Article thumbnail

Pharmacogenomic strategy for individualizing antidepressant therapy

By Keh-Ming Lin, Roy H. Perils and Yu-Jui Yvonne Wan


Despite remarkable progress, pharmacotherapy in general, including that for the treatment of depressive conditions, has often ignored the magnitude and clinical significance of the huge interindividual variations in pharmacokinetics and pharmacodynamics, resulting in poor compliance, suboptimal therapeutic effects, and treatment resistance. Advances in pharmacogenomics and computer modeling technologies hold promise for achieving the goals of “individualized” (“personalized”) medicine. However, the challenges for realizing such goals remain substantial. These include the packaging and interpretation of genotyping results, changes in medical practice (innovation diffusion), and infrasiructural, financing, ethical, and organizational issues related to the use of new information

Topics: Translational Research
Publisher: Les Laboratoires Servier
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder.
  2. (1998). A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet.
  3. (1999). A functional polymorphism in the promoter region of monoamine oxidase-A gene and mood disorders. Mol Psychiatry.
  4. (1999). A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry.
  5. (1998). A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen Psychiatry.
  6. (1997). Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium. Biol Psychiatry.
  7. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression.
  8. (1989). Alpha-Acid Glycoprotein: Genetics, Biochemistry, Physiological Functions and Pharmacology.
  9. (1995). Altered striatal dopamine reuptake site densities in habitually violent and non-violent alcoholics. Nat Med.
  10. Association between the low-functional MAO-A gene promoter and pathological gambling.
  11. (1998). Association between the tryptophan hydroxylase gene and manic-depressive illness. Arch Gen Psychiatry.
  12. (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region.
  13. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder.
  14. (2002). Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry.
  15. Beta-1-adrenergic receptor gene in major depression: Influence on antidepressant treatment response.
  16. Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des.
  17. (2002). but not fluvoxamine, normalizes the blunted REM sleep response to clonidine in depressed patients: implications for subsensitivity of alpha2-adrenergic receptors in depression. Psychiatry Res.
  18. (1996). Caring for Depression: a RAND Study:
  19. Correlation between platelet alpha-adrenoreceptors and symptom severity in major depression.
  20. Cross-national epidemiology of major depression and bipolar disorder.
  21. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry.
  22. Does psychological distress predict the risk of ischemic stroke and transient ischemic attack? The Caerphilly Study.
  23. Dopamine transporter gene polymorphism and alcoholism.
  24. (1996). Dopamine transporter gene polymorphism and psychiatric symptoms seen in schizophrenic patients at their first episode.
  25. Evidence for linkage disequilibrium between the dopamine transporter and bipolar disorder.
  26. Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer.
  27. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry.
  28. (1999). Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes.
  29. (2001). Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attentiondeficit/hyperactivity disorder. Biol Psychiatry.
  30. Human dopamine transporter gene polymorphism (VNTR) and alcoholism.
  31. (1992). Human dopamine transporter gene(DAT1) maps to chromosome 5p15.3 and displays a VNTR.
  32. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
  33. (2002). Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry.
  34. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry.
  35. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry.
  36. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry.
  37. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha 2A-adrenoceptors. Mol Psychiatry.
  38. (1999). No association between serotonin-2A receptor gene polymorphism and psychotic symptomatology of mood disorders. Psychiatry Res.
  39. Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs.
  40. Pharmacogenetics and drug metabolism of newer antidepressant agents.
  41. (1998). Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry.
  42. Polymorphisms in the ABC drug transporter gene MDR1.
  43. Polymorphisms in the human AH receptor. Chemico-Biological Interactions.
  44. (1995). Recent studies on norepinephrine systems in mood disorders.
  45. (1998). Serotonin transporter candidate gene studies in affective disorders and personality: promises and potential pitfalls. Mol Psychiatry.
  46. Serotonin transporter gene polymorphism and antidepressant response.
  47. Serotonin transporter genetic variation and the response of the human amygdala.
  48. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Paper presented at: American College of Neuropsychopharmacology.
  49. (1996). Socioeconomic burden of subsyndromal depressive symptoms and major depression inasampleofthe general population.
  50. SSRIs antidepressant activity is influenced by G‚3 variants variants.
  51. Subthreshold depression and depressive disorder: clinical characteristics of general medical and mental health specialty outpatients.
  52. Suicide and primary affective disorders.
  53. The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety.
  54. The apolipoprotein E e4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biol Psychiatry.
  55. The catechol-O-methyltransferase Val108//158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression.
  56. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry.
  57. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder.
  58. (1999). The T102C Polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis.
  59. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population.
  60. (1995). World Mental Health: Problems and Priorities in Developing Countries.